ACACIA-HCM supports neither the word “cure” nor the idea of an already established new standard. It provides something more precise: a statistically established functional benefit in a controlled trial, accompanied by a safety signal that requires monitoring and calibration.
Results
In this randomized double-blind trial, 517 adults received aficamten or placebo; after 36 weeks, KCCQ-CSS increased by 11.4 points versus 8.4 points, and peak oxygen uptake by 0.64 ml/kg/min versus -0.03 ml/kg/min.
An ejection fraction below 50% occurred in about 10% of the aficamten group versus 1% of the placebo group; serious adverse events were also more frequent with treatment.
The positive result therefore concerns exercise capacity and patient-reported health status. It does not yet demonstrate lower mortality or hospitalization.
What the evidence changes
The signal matters because this nonobstructive form of the disease lacked a firmly established specific treatment. Full publication moves the hypothesis from a promising mechanism to an option supported by an advanced controlled trial.
Limits
The average questionnaire effect remains modest. Industry funding and declared ties require close reading without invalidating the protocol. Follow-up remains limited, and echocardiographic monitoring is part of treatment rather than a secondary detail.
Sources
Confidence
High confidence in this trial’s results; consensus on the drug’s place in care is still emerging.